What does Artelo Biosciences do?
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company developing therapies that alter lipid signaling, including the endocannabinoid system and fatty-acid-binding proteins. Incorporated in Nevada and headquartered in Solana Beach, California, it reports one life-science segment and operates through a small internal team supported by universities, contract research organizations, clinical sites, consultants, and licensed intellectual property.
Artelo is best understood as a portfolio of scientific options, not an operating drug franchise. It has no approved product, product sales, or commercial infrastructure. Value depends on clinical evidence, regulatory progress, defensible patents, and financing or partnering. The official pipeline overview organizes three programs with different mechanisms and development stages.
Why does lipid signaling matter to the strategy?
Lipid pathways influence pain, inflammation, appetite, mood, immunity, and cellular behavior. Artelo's thesis is that selective modulation can produce therapeutic effects while limiting central nervous system liabilities. Its pipeline therefore combines a peripherally restricted cannabinoid agonist, a selective FABP5 inhibitor, and a proprietary CBD cocrystal.
What kind of company is Artelo today?
| Research dimension | Artelo's current position | Why it matters |
|---|---|---|
| Business stage | Clinical-stage, pre-revenue pharmaceutical developer | Financial analysis centers on cash burn, financing capacity, and probability-adjusted pipeline value rather than sales growth. |
| Reporting structure | One life-science segment | The three programs diversify scientific risk, but they do not produce separate commercial revenue streams yet. |
| Operating model | Lean internal team plus outsourced research and clinical execution | The model reduces fixed infrastructure but increases dependence on licensors, CROs, manufacturers, and investigators. |
| Geographic footprint | United States parent with subsidiaries in Ireland, England and Wales, and Canada | Development spans multiple regulatory systems, currencies, clinical sites, and research partners. |
How does Artelo make money before it has a product?
Artelo does not yet earn recurring revenue. It acquires or creates intellectual property, funds development, and seeks evidence that can support partnership, licensing, co-development, acquisition, or eventual commercialization. Future economics could include upfront payments, milestones, royalties, or product sales. Until then, operations depend on equity, warrants, notes, and other financing.
Which contractual economics sit behind the pipeline?
ART27.13 was originally developed by AstraZeneca and licensed through NEOMED, now adMare BioInnovations. Its agreement provides for up to $200.0 million of milestones plus mid- to high-single-digit royalties. The Stony Brook FABP license behind ART26.12 carries low-single-digit royalties and milestones including $150,000 at first Phase 2, $250,000 at first Phase 3, and $1.5 million at first commercial sale.
| Economic path | Potential inflow to Artelo | Potential outflow or constraint |
|---|---|---|
| Partnering before approval | Upfront cash, shared development costs, and milestone consideration | Artelo may surrender economics, control, or geographic rights to reduce funding risk. |
| Successful licensed product | Product sales or royalties retained from a partner | Royalties and milestones owed to upstream licensors reduce net economics. |
| Equity and warrant financing | Immediate liquidity for trials and public-company costs | Share issuance, warrants, and pre-funded warrants create dilution and an equity overhang. |
| Externally funded study | Clinical evidence generated with limited direct study funding | Timing and execution depend partly on third-party sponsors and investigators. |
What is the central business-model tension?
Which pipeline programs matter most?
Selective FABP5 inhibitor in Phase 1 development as a peripherally acting, non-opioid, non-steroidal analgesic, initially focused on chemotherapy-induced peripheral neuropathy.
Peripherally selective dual CB1/CB2 agonist being evaluated for cancer-related anorexia and cachexia, with additional externally funded glaucoma work and exploratory supportive-care applications.
Wholly owned CBD and tetramethylpyrazine cocrystal designed to improve solid-state consistency, bioavailability, and pharmacokinetic performance for anxiety, depression, PTSD, and other potential uses.
Why is ART26.12 increasingly the lead strategic asset?
ART26.12 crossed its first human threshold in a 49-volunteer Phase 1 single-ascending-dose study. The company reported mild, transient adverse events, no drug-related adverse events in the blinded dataset, linear pharmacokinetics, and exposure above projected therapeutic levels. Multiple-ascending-dose enrollment is expected in Q4 2026. The ART26.12 program page explains the mechanism, and a July 16, 2026 osteoarthritis update added nonclinical pain evidence. The unresolved issue is efficacy in patients.
What does ART27.13's interim clinical signal show?
CAReS had enrolled 32 participants by December 31, 2025. Among 18 evaluable patients, five receiving 1,300 micrograms gained 6.38% mean body weight after 12 weeks, while six placebo patients lost 5.42%; one-month lean mass changed by +4.23% versus -3.15%. The groups are small and interim, but the signal supports partnership discussions. The official ART27.13 page explains the rationale.
Where does ART12.11 fit?
ART12.11 is wholly owned. Its U.S. composition-of-matter patent runs to December 10, 2038, with grants or validations in 21 additional countries. The cocrystal is intended to improve CBD stability, dissolution, and absorption, but remained preclinical in FY2025. Management planned first-in-human work for the first half of 2026; no start had been publicly confirmed by July 18, 2026. The ART12.11 program page describes the patent and formulation thesis.
What do Artelo's latest financial results show?
The latest reporting package is the quarter ended March 31, 2026. Artelo remained pre-revenue, so the most informative lines are operating expense mix, net loss, operating cash burn, financing inflows, cash, and liabilities. The quarter was dominated by a $11.0 million gross private placement that materially repaired liquidity after year-end cash had fallen to $0.6 million.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | No commercial revenue absorbs development costs. |
| R&D expense | $0.8M | $1.4M | Down 44.1%, reflecting research timing. |
| G&A expense | $1.9M | $1.0M | Up 92.6%, largely from financing-related professional fees. |
| Operating expenses | $2.7M | $2.4M | Higher administrative costs offset lower R&D. |
| Net loss | $3.0M | $2.4M | Loss rose 24.7%, including financing and derivative effects. |
| Operating cash burn | $1.2M | $1.6M | Cash use improved 25.4% after noncash and working-capital adjustments. |
These figures come from Artelo's Q1 2026 business update and the detailed March 31, 2026 Form 10-Q.
How did the expense mix change?
Why was cash burn lower than the accounting loss?
How strong is the balance sheet after the 2026 financing?
At March 31, 2026, current assets were $10.421 million against $5.828 million of current liabilities, a current ratio near 1.8 times. That was much stronger than December 31, 2025, when cash was $0.600 million and equity was a $1.272 million deficit. Because the repair came from securities issuance rather than product cash flow, structural funding risk remains.
What did the March financing change?
The private placement issued 81,000 common shares, 3,107,407 pre-funded warrants, and 6,376,814 common warrants exercisable at $3.20. Gross proceeds were $10.997 million and net proceeds $10.032 million. Full cash exercise could yield about $31.4 million, but market price, registration, ownership blockers, and investor behavior make that contingent—not committed—capital.
What does capital allocation tell researchers?
| Capital item | Official figure and period | Analytical meaning |
|---|---|---|
| FY2025 operating cash use | $8.520M | Annual burn exceeded year-end liquidity. |
| FY2025 net financing cash | $6.867M | External financing was already essential. |
| Q1 2026 financing cash | $10.860M | Financing inflow exceeded quarterly burn by more than nine times. |
| Q1 2026 current liabilities | $5.828M | Payables, notes, and derivative liabilities consume liquidity. |
| Post-quarter debt repayment | $0.720M for March notes plus $0.430M on May 2025 notes | The raise partly repaid bridge financing. |
| Authorized shares | Increased from 166.7M to 500.0M on July 17, 2026 | The authorization expands both financing flexibility and dilution capacity. |
The full-year baseline is available in the FY2025 Form 10-K. Artelo has more runway but no self-funding engine; clinical scope and vendor timing can quickly change burn.
Which turning points shaped Artelo's strategy?
-
2011Artelo was incorporated in Nevada. Its long pre-commercial history explains accumulated losses and repeated financing.
-
2017Gregory D. Gorgas became president, chief executive officer, secretary, and director, creating leadership continuity in partnering and financing.
-
2018–2019The company licensed the Stony Brook FABP platform and exercised its option for exclusive worldwide rights to ART27.13, creating today's two licensed pipeline pillars.
-
2021–2023CAReS began dosing ART27.13 in cancer-related anorexia, moved through Phase 1b, and entered Phase 2a across 18 sites in five countries.
-
2024–2025FDA clearance enabled ART26.12's first-in-human study; the 49-subject Phase 1 result validated FABP5 in humans, while CAReS produced a partnering signal.
-
2026A private placement repaired liquidity; Nasdaq compliance returned; ART26.12 added evidence; and stockholders expanded authorized shares.
What creates an advantage—and where is the moat still unproven?
What resources could become defensible?
Artelo's potential advantages are its patent estate, licensed platform rights, human data, formulation know-how, and outsourced research network. FY2025 disclosures listed six U.S. and 11 foreign issued patents plus 25 pending applications for ART26.12-related chemistry; ART12.11 added two U.S. and six foreign patents. These resources may be difficult to reproduce exactly, but their value depends on clinical utility.
The qualifier is important: patents do not prove clinical efficacy, regulatory approval, reimbursement, manufacturing scalability, or market adoption. ART27.13 and ART26.12 are also subject to license obligations, and licensors may retain influence over patent prosecution. Artelo's small size means larger competitors can fund parallel mechanisms, broader trials, and commercialization more easily.
Who are the relevant competitors?
| Competitive arena | Named companies or alternatives cited by Artelo | Artelo's differentiation claim | Unresolved test |
|---|---|---|---|
| Cancer supportive care | Helsinn, NGM Biopharmaceuticals, Pfizer, existing appetite and symptom-management approaches | Peripheral CB1/CB2 activity intended to improve weight and activity without central psychoactive effects | A larger controlled study must confirm CAReS. |
| Pain and neuropathy | Large pharmaceutical developers, opioids, NSAIDs, anticonvulsants, antidepressants, and emerging non-opioid mechanisms | Selective FABP5 inhibition with a non-opioid, non-steroidal, peripherally acting profile | Patient efficacy and dose selection remain unproven. |
| Cannabinoid and CBD therapeutics | Jazz Pharmaceuticals, Skye Bioscience, Longboard Pharmaceuticals, and approved or developing cannabinoid formulations | A patented CBD:TMP cocrystal intended to improve pharmaceutical consistency and bioavailability | Human formulation, safety, pharmacokinetics, and indication choice remain unproven. |
| Drug-development capacity | Novartis and other well-capitalized biopharma companies | Small-company speed, focused mechanisms, and academic collaborations | Scale disadvantages span trials, manufacturing, regulation, and commercialization. |
Who owns Artelo and how is it governed?
Artelo has one common share class with one vote per share. The proxy used 2,848,540 shares outstanding on May 22, 2026, disclosed no holder above 5%, and reported 93,282 shares, or 3.2%, beneficially owned by directors and officers as a group. Management influence therefore comes through board roles, contracts, options, and execution rather than voting control.
What does the board structure signal?
The board had seven directors on May 22, 2026, six independent under Nasdaq standards. Its three staggered classes can slow a rapid change in control. The board met 12 times in FY2025, with every director attending at least 75% of applicable meetings. Gregory Gorgas has led Artelo since April 2017; Mark Spring became CFO in November 2025, separating that role from the CEO.
| Governance fact | Latest disclosed figure | Why it matters |
|---|---|---|
| Board independence | 6 of 7 directors | Independent oversight matters across financing, compensation, and clinical risk. |
| CEO beneficial ownership | 42,528 shares; 1.5% | Economic alignment exists but does not give the CEO voting control. |
| All directors and officers | 93,282 shares; 3.2% | Outside investors make financing sentiment especially important. |
| FY2025 CEO compensation | $1.223M total | Executive cost is material for a seven-employee pre-revenue company. |
| July 17, 2026 annual meeting | 41.2% of record-date shares represented | Stockholders raised authorized common shares to 500.0M, prioritizing financing flexibility. |
Ownership and board data are drawn from the 2026 definitive proxy statement. The meeting outcome is reported in the July 17, 2026 Form 8-K.
Why does ownership matter for financing?
With dispersed ownership, stock price, Nasdaq compliance, registration capacity, and investor appetite become operating variables. Warrant exercises and ownership blockers can change share counts quickly, so analysis should reconcile the latest 10-Q, proxy, 8-K filings, and warrant terms.
What opportunities and risks could change Artelo's outlook?
Which catalysts deserve the most attention?
What are the most material constraints?
| Risk | Company-specific exposure | Financial line or milestone affected | What to monitor |
|---|---|---|---|
| Clinical efficacy | ART26.12 efficacy is unproven; ART27.13 evidence comes from small interim groups. | Pipeline value, future R&D, partnering terms | Randomization, sample size, dose response, durability, and safety. |
| Financing and dilution | No revenue, a going-concern warning, warrants, and expanded authorized shares. | Cash, shares outstanding, per-share value | Cash, burn, equity sales, and warrant exercises. |
| License dependence | ART27.13 and FABP rely on third-party licenses. | Gross economics, patent rights, program continuity | Compliance with license, royalty, and milestone terms. |
| Patent and competitive risk | Competitors may design around patents or reach approval first. | Exclusivity period, legal expense, commercial probability | Patent events, freedom to operate, and competitor trials. |
| Outsourcing and supply chain | External research, manufacturing, and clinical partners perform essential work. | Trial timing, accrued expenses, cash burn | Enrollment, manufacturing, vendors, and protocol delays. |
| Regulatory and reimbursement | Approval, pricing, cannabinoid rules, and payer economics can change value. | Approval timing, pricing, market access, terminal margins | Regulatory feedback, trial holds, labeling, and reimbursement evidence. |
Why does Artelo matter for valuation?
A conventional revenue-based DCF is unsuitable because Artelo has no approved product or recurring revenue. A probability-adjusted pipeline model should estimate approval odds, timing, patients, price, penetration, gross-to-net deductions, manufacturing cost, royalties, milestones, selling costs, taxes, and patent duration. Corporate expense and expected financing dilution must then be deducted.
Which KPIs should a model update first?
- Cash and quarterly operating burn: determine how many milestones can be reached before another financing.
- Fully diluted share count: include common stock, pre-funded warrants, common warrants, placement-agent warrants, options, and financing commitments where appropriate.
- Clinical enrollment and readout dates: shift expected cash flows and the timing of probability changes.
- Dose, safety, and efficacy measures: update program-specific success assumptions rather than applying a generic biotech probability.
- Partnering terms: separate upfront, milestones, cost sharing, royalties, territorial rights, and retained obligations.
- R&D versus G&A mix: distinguish spending that advances the pipeline from recurring public-company and financing overhead.
What is the key takeaway from Artelo Biosciences analysis?
Artelo is a useful small-cap biotechnology case study: a seven-employee company assembled multiple mechanisms through licensing, academic relationships, outsourcing, and proprietary formulation work, then used early evidence to seek partners and capital. The 49-subject ART26.12 Phase 1 study, interim ART27.13 weight and lean-mass findings, and 2026 pain-model data improved the scientific story; the March financing lifted cash to $10.3 million.
The weakness is clear: no revenue, a continuing going-concern warning, Q1 2026 G&A above R&D, and substantial warrant and authorized-share capacity. Artelo must turn scientific breadth into reproducible clinical progress before financing costs overwhelm program option value.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.